Sign in
Not yet recruitingPhase 2

A Study to Learn About the Study Medicine Called Aztreonam-Avibactam in Neonates and Infants Less Than 9 Months of Age With Suspected or Confirmed Infections Due to Gram-Negative Bacteria

Key facts

Who runs it
Pfizer Inc.
Where
Bulgaria, Greece, Hungary, Italy, Slovakia, and Spain20 sites in 6 countriesChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 2
People taking part
18 people, planned
Started
1 Jul 2025
Expected to end
3 Aug 2028
Type of study
Interventional
Record updated
15 September 2026

Who can take part

Age
Up to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Hospitalized with age from birth <9 months, including preterm birth
  • Part A: Receiving IV antibiotics for treatment of suspected or confirmed bacterial infection, including but not limited to cIAI, cUTI, HAP/VAP, BSI, or sepsis
  • Part B: Suspected or confirmed gram-negative bacterial infection requiring IV antibiotics, including but not limited to cIAI, cUTI, HAP/VAP, BSI, or sepsis

Who cannot take part

  • Received any other investigational medicinal product within the longer of 30 days or 5 half-lives before enrollment
  • Part B Only: Received >24 hours of systemic antibiotic treatment for gram-negative organisms at time of enrollment, unless documented treatment failure or lack of improvement in at least one objective sign or symptom of infection after ≥48 hours of antibiotics
  • Any medical or laboratory abnormality that may increase the risk of study participation or, in the investigator’s judgment, make the participant inappropriate for the study
  • Severe renal impairment or known significant renal disease, as evidenced by elevated serum creatinine at screening, or urinary output <0.5 mL/kg/h for 6 consecutive hours or requirement for dialysis

This trial has no sites in United States.

It has sites in 6 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

Evaluate the PK of ATM-AVI for the treatment of gram-negative bacterial infections including complicated urinary tract infection (cUTI), complicated intraabdominal infection (cIAI), hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP), blood stream infection (BSI), or sepsis in hospitalized neonates and infants from birth to <9 month of age.

Read full original descriptionShow less

Evaluate the safety and tolerability of ATM-AVI in hospitalized neonates and infants from birth to <9 months.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
C3601010: A Phase 2A, 2-Part, Open-Label, Non-Randomized, Multicenter, Single and Multiple Dose Trial to Evaluate Pharmacokinetics, Safety and Tolerability of Aztreonam and Avibactam ± Metronidazole in Neonates and Infants From Birth to Less Than 9 Months of Age With Suspected or Confirmed Infections Due to Gram-Negative Pathogens Requiring Intravenous Antibiotic Treatment
Record updated
15 September 2026